Iqvia Holdings Inc (NYSE:IQV) Director John Connaughton sold 1,163,191 shares of Iqvia stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $118,645,482.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
John Connaughton also recently made the following trade(s):
- On Tuesday, September 19th, John Connaughton sold 1,030,429 shares of Iqvia stock. The shares were sold at an average price of $94.87, for a total value of $97,756,799.23.
Shares of Iqvia Holdings Inc (IQV) traded down $0.41 during midday trading on Friday, hitting $97.90. The company had a trading volume of 839,812 shares, compared to its average volume of 1,141,990. The firm has a market cap of $20,447.29, a PE ratio of 337.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.61. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia Holdings Inc has a twelve month low of $74.80 and a twelve month high of $110.67.
Several equities analysts have recently issued reports on the company. Royal Bank of Canada assumed coverage on Iqvia in a research report on Tuesday, September 19th. They set an “outperform” rating and a $116.00 price target on the stock. KeyCorp reiterated a “buy” rating and set a $100.00 price target on shares of Iqvia in a research report on Sunday, September 24th. Zacks Investment Research upgraded Iqvia from a “hold” rating to a “buy” rating and set a $114.00 price target on the stock in a research report on Saturday, October 21st. Barclays lifted their price target on Iqvia from $100.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Finally, Stifel Nicolaus upgraded Iqvia from a “hold” rating to a “buy” rating and lifted their price target for the company from $92.00 to $128.00 in a research report on Friday, October 27th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and a consensus target price of $106.94.
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.